The following is a summary of the Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Ono Pharmaceutical reported Q1 revenue of ¥502.7 billion, marking their first time exceeding ¥500 billion.

• Their recorded operating profit, including cost of sales, was ¥127.1 billion, up by ¥17.1 billion year-on-year.

• The company also showed an increase of ¥15.3 billion year-on-year in the earnings for the year attributable to the company, reaching ¥128 billion.

• For FY '24, they projected a decrease in revenue to ¥450 billion and also a decrease in operating profit to ¥122 billion due to various factors, including declined royalty rates.

• The company emphasized their continued increase in dividend payment, aiming for a 40% payout ratio.

Business Progress:

• Key business developments included delays in filing for specific cancer treatments, completion of filings for combination therapies, and focus on gastric and lung cancer treatments with an expected product volume increase despite market challenges.

• Positive results continued with their Opdivo product, maintaining a significant market share in treating various types of cancers and showing strong long-term efficacy, leading to planned expansion into additional indications.

• In face of increasing competition, the company affirmed their commitment to keep their top position in the gastrointestinal field.

• Additionally, Ono Pharmaceutical acknowledged their acquisition of Deciphera Pharmaceuticals, expecting its financial impact in the second half of their current fiscal year.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.